IMbrave 050: A Phase III Trial of Atezolizumab Plus Bevacizumab in High-Risk Hepatocellular Carcinoma after Curative Resection or Ablation

References

• Villanueva A . Hepatocellular Carcinoma. N. Engl. J. Med.380(15), 1450–1462 (2019).
   PubMed Web of Science ®Google Scholar
• Forner A , ReigM, BruixJ. Hepatocellular carcinoma. Lancet391(10127), 1301–1314 (2018).
   PubMed Web of Science ®Google Scholar
• Rich NE , YoppAC, SingalAG. Medical management of hepatocellular carcinoma. J. Oncol. Pract.13(6), 356–364 (2017).
   PubMed Web of Science ®Google Scholar
• Kinoshita A , OnodaH, FushiyaN, KoikeK, NishinoH, TajiriH. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J. Hepatol.7(3), 406–424 (2015).
   PubMedGoogle Scholar
• Yau T , TangVY, YaoTJ, FanST, LoCM, PoonRT. Development of Hong Kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology146(7), 1691–1700 (2014).
   PubMed Web of Science ®Google Scholar
• Forner A , LlovetJM, BruixJ. Hepatocellular carcinoma. Lancet379(9822), 1245–1255 (2012).
   PubMed Web of Science ®Google Scholar
• Omata M , ChengAL, KokudoNet al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol. Int.11(4), 317–370 (2017).
   PubMed Web of Science ®Google Scholar
• Torzilli G , BelghitiJ, KokudoNet al. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann. Surg.257(5), 929–937 (2013).
   PubMed Web of Science ®Google Scholar
• Li ZL , YuJJ, GuoJWet al. Liver resection is justified for multinodular hepatocellular carcinoma in selected patients with cirrhosis: a multicenter analysis of 1,066 patients. Eur. J. Surg. Oncol.45(5), 800–807 (2019).
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver . EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J. Hepatol.69(1), 182–236 (2018).
   PubMed Web of Science ®Google Scholar
• Heimbach JK , KulikLM, FinnRSet al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology67(1), 358–380 (2018).
   PubMed Web of Science ®Google Scholar
• Liang L , XingH, ZhangHet al. Surgical resection versus transarterial chemoembolization for BCLC intermediate stage hepatocellular carcinoma: a systematic review and meta-analysis. HPB20(2), 110–119 (2018).
   PubMed Web of Science ®Google Scholar
• Farinati F , VaninV, GiacominAet al. BCLC stage B hepatocellular carcinoma and transcatheter arterial chemoembolization: a 20-year survey by the Italian Liver Cancer group. Liver Int.35(1), 223–231 (2015).
   PubMed Web of Science ®Google Scholar
• Lim KC , ChowPKH, AllenJC, SiddiquiFJ, ChanESY, TanSB. Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria. Br. J. Surg.99(12), 1622–1629 (2012).
   PubMed Web of Science ®Google Scholar
• Zhong JH , RodriguezAC, KeY, WangYY, WangL, LiLQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine94(3), e396 (2015).
   PubMed Web of Science ®Google Scholar
• Li L , ZhangJ, LiuX, LiX, JiaoB, KangT. Clinical outcomes of radiofrequency ablation and surgical resection for small hepatocellular carcinoma: a meta-analysis. J. Gastroenterol. Hepatol.27(1), 51–58 (2012).
   PubMed Web of Science ®Google Scholar
• Imamura H , MatsuyamaY, TanakaEet al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol.38(2), 200–207 (2003).
   PubMed Web of Science ®Google Scholar
• Aufhauser DD Jr , SadotE, MurkenDRet al. Incidence of occult intrahepatic metastasis in hepatocellular carcinoma treated with transplantation corresponds to early recurrence rates after partial hepatectomy. Ann. Surg.267(5), 922–928 (2018).
   PubMed Web of Science ®Google Scholar
• Chan AWH , ZhongJ, BerhaneSet al. Development of pre and post-operative models to predict early recurrence of hepatocellular carcinoma after surgical resection. J. Hepatol.69(6), 1284–1293 (2018).
   PubMed Web of Science ®Google Scholar
• Utsunomiya T , ShimadaM, KudoMet al. A comparison of the surgical outcomes among patients with HBV-positive, HCV-positive, and Non-B Non-C hepatocellular carcinoma: a nationwide study of 11,950 patients. Ann. Surg.261(3), 513–520 (2015).
   PubMed Web of Science ®Google Scholar
• Jung S-M , KimJM, ChoiG-Set al. Characteristics of early recurrence after curative liver resection for solitary hepatocellular carcinoma. J. Gastrointest. Surg.23(2), 304–311 (2019).
   PubMed Web of Science ®Google Scholar
• Tabrizian P , JibaraG, ShragerB, SchwartzM, RoayaieS. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann. Surg.261(5), 947–955 (2015).
   PubMed Web of Science ®Google Scholar
• Lu LC , ChengAL, PoonRT. Recent advances in the prevention of hepatocellular carcinoma recurrence. Semin. Liver Dis.34(4), 427–434 (2014).
   PubMed Web of Science ®Google Scholar
• Zhong JH , ZhongQL, LiLQ, LiH. Adjuvant and chemopreventive therapies for resectable hepatocellular carcinoma: a literature review. Tumour Biol.35(10), 9459–9468 (2014).
   PubMedGoogle Scholar
• Bruix J , TakayamaT, MazzaferroVet al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a Phase III, randomised, double-blind, placebo-controlled trial. Lancet Oncol.16(13), 1344–1354 (2015).
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB , SangroB, YauTet al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, Phase I/II dose escalation and expansion trial. Lancet389(10088), 2492–2502 (2017).
   PubMed Web of Science ®Google Scholar
• Lee M , RyooBY, HsuCHet al. LBA39Randomised efficacy and safety results for atezolizumab (Atezo)+bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC). Ann. Oncol.30(Suppl.5), v875 (2019).
   PubMedGoogle Scholar
• Zhu AX , FinnRS, EdelineJet al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label Phase II trial. Lancet Oncol.19(7), 940–952 (2018).
   PubMed Web of Science ®Google Scholar
• Finn RS , RyooBY, MerlePet al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, Phase III trial. J. Clin. Oncol.38(3), 192–202 (2019)
   Web of Science ®Google Scholar
• Yau T , ParkJW, FinnRSet al. LBA38_PRCheckMate 459: a randomized, multi-center Phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC). Ann. Oncol.30(Suppl.5), v874 (2019).
   Google Scholar
• Motzer RJ , PenkovK, HaanenJet al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1103–1115 (2019).
   PubMed Web of Science ®Google Scholar
• Socinski MA , JotteRM, CappuzzoFet al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N. Engl. J. Med.378(24), 2288–2301 (2018).
   PubMed Web of Science ®Google Scholar
• Rini BI , PlimackER, StusVet al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N. Engl. J. Med.380(12), 1116–1127 (2019).
   PubMed Web of Science ®Google Scholar
• Llovet JM , MontalR, SiaD, FinnRS. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat. Rev. Clin. Oncol.15(10), 599–616 (2018).
   PubMed Web of Science ®Google Scholar
• Chen DS , HurwitzH. Combinations of bevacizumab with cancer immunotherapy. Cancer J.24(4), 193–204 (2018).
   PubMed Web of Science ®Google Scholar
• Hegde PS , WallinJJ, MancaoC. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin. Cancer Biol.52, 117–124 (2018).
   PubMed Web of Science ®Google Scholar
• Fukumura D , KloepperJ, AmoozgarZ, DudaDG, JainRK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol.15(5), 325–340 (2018).
   PubMed Web of Science ®Google Scholar
• Cheng A-L , QinS, IkedaMet al. LBA3IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann. Oncol.30(Suppl.9), ix186 (2019).
   Google Scholar
• Brown ZJ , GretenTF, HeinrichB. Adjuvant treatment of hepatocellular carcinoma: prospect of immunotherapy. Hepatology70(4), 1437–1442 (2019).
   PubMed Web of Science ®Google Scholar
• Takayama T , SekineT, MakuuchiMet al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet356(9232), 802–807 (2000).
   PubMed Web of Science ®Google Scholar
• Lee JH , LeeJH, LimYSet al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology148(7), 1383–1391.e1386 (2015).
   PubMed Web of Science ®Google Scholar
• Peng BG , LiangLJ, HeQet al. Tumor vaccine against recurrence of hepatocellular carcinoma. World J. Gastroenterol.11(5), 700–704 (2005).
   PubMed Web of Science ®Google Scholar
• Kuang M , PengBG, LuMDet al. Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin. Cancer Res10(5), 1574 (2004).
   PubMed Web of Science ®Google Scholar
• Gabrielson A , WuY, WangHet al. Intratumoral CD3 and CD8 T-cell densities associated with relapse-free survival in HCC. Cancer Immunol Res.4(5), 419–430 (2016).
   PubMed Web of Science ®Google Scholar
• Fu J , ZhangZ, ZhouLet al. Impairment of CD4+ cytotoxic T cells predicts poor survival and high recurrence rates in patients with hepatocellular carcinoma. Hepatology58(1), 139–149 (2013).
   PubMed Web of Science ®Google Scholar
• Xiao YS , GaoQ, XuXNet al. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection. PLoS ONE8(8), e70345 (2013).
   PubMed Web of Science ®Google Scholar
• Foerster F , HessM, Gerhold-AyAet al. The immune contexture of hepatocellular carcinoma predicts clinical outcome. Sci. Rep.8(1), 5351–5351 (2018).
   PubMedGoogle Scholar
• Sun L , XuG, LiaoWet al. Clinicopathologic and prognostic significance of regulatory T cells in patients with hepatocellular carcinoma: a meta-analysis. Oncotarget8(24), 39658–39672 (2017).
   PubMedGoogle Scholar
• Gao Q , QiuS-J, FanJet al. Intratumoral balance of regulatory and cytotoxic T Cells Is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol.25(18), 2586–2593 (2007).
   PubMed Web of Science ®Google Scholar
• Gao X-H , TianL, WuJet al. Circulating CD14+HLA-DR-/low myeloid-derived suppressor cells predicted early recurrence of hepatocellular carcinoma after surgery. Hepatol. Res.47(10), 1061–1071 (2017).
   PubMed Web of Science ®Google Scholar
• Arihara F , MizukoshiE, KitaharaMet al. Increase in CD14+HLA-DR-/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis. Cancer Immunol. Immunother.62(8), 1421–1430 (2013).
   PubMed Web of Science ®Google Scholar
• Iwata T , KondoY, KimuraOet al. PD-L1(+)MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment. Sci. Rep.6, 39296 (2016).
   PubMed Web of Science ®Google Scholar
• Zhu X-D , ZhangJ-B, ZhuangP-Yet al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J. Clin. Oncol.26(16), 2707–2716 (2008).
   PubMed Web of Science ®Google Scholar
• Capece D , FischiettiM, VerzellaDet al. The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-associated macrophages. BioMed Res. Int.2013, 15 (2013).
   Web of Science ®Google Scholar
• Calderaro J , RousseauB, AmaddeoGet al. Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology64(6), 2038–2046 (2016).
   PubMed Web of Science ®Google Scholar
• Shi F , ShiM, ZengZet al. PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int. J. Cancer128(4), 887–896 (2011).
   PubMed Web of Science ®Google Scholar
• Liu G-M , LiX-G, ZhangY-M. Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis. Cancer Cell Int.19, 22–22 (2019).
   PubMed Web of Science ®Google Scholar
• Lu C , RongD, ZhangBet al. Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities. Mol. Cancer18(1), 130 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang X , FuX, LiT, YanH. The prognostic value of myeloid derived suppressor cell level in hepatocellular carcinoma: a systematic review and meta-analysis. PLoS ONE14(12), e0225327 (2019).
   PubMed Web of Science ®Google Scholar
• Lu LC , ChangCJ, HsuCH. Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives. J. Hepatocell. Carcinoma6, 71–84 (2019).
   PubMed Web of Science ®Google Scholar
• McDermott DF , HuseniMA, AtkinsMBet al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med.24(6), 749–757 (2018).
   PubMed Web of Science ®Google Scholar
• Zhao HQ , LiWM, LuZQ, YaoYM. Roles of Tregs in development of hepatocellular carcinoma: a meta-analysis. World J. Gastroenterol.20(24), 7971–7978 (2014).
   PubMed Web of Science ®Google Scholar
• Kalathil S , LugadeAA, MillerA, IyerR, ThanavalaY. Higher frequencies of GARP+CTLA-4+Foxp3+ T regulatory cells and myeloid-derived suppressor cells in hepatocellular carcinoma patients are associated with impaired T-cell functionality. Cancer Res.73(8), 2435 (2013).
   PubMed Web of Science ®Google Scholar
• Sia D , JiaoY, Martinez-QuetglasIet al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology153(3), 812–826 (2017).
   PubMed Web of Science ®Google Scholar
• Hilmi M , NeuzilletC, CalderaroJ, LafdilF, PawlotskyJ-M, RousseauB. Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J. Immunother. Cancer7(1), 333 (2019).
   PubMed Web of Science ®Google Scholar
• Li G , Staveley-O’CarrollKF, KimchiET. Potential of radiofrequency ablation in combination with immunotherapy in the treatment of hepatocellular carcinoma. J. Clin. Trials6(2), 257 (2016).
   PubMedGoogle Scholar
• Mizukoshi E , YamashitaT, AraiKet al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology57(4), 1448–1457 (2013).
   PubMed Web of Science ®Google Scholar
• Martins-Filho SN , PaivaC, AzevedoRS, AlvesVaF. Histological grading of hepatocellular carcinoma – a systematic review of literature. Front. Med.4, 193 (2017).
   Web of Science ®Google Scholar
• Zhou J , SunHC, WangZet al. Guidelines for diagnosis and treatment of primary liver cancer in China (2017 Edition). Liver Cancer7(3), 235–260 (2018).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar